Hence, these results suggest that HGFR-mTOR-ULK1 cascade is responsible for HGFR inhibitor-mediated autophagy, and HGFR inhibitors combined with autophagy inhibitors could be a promising choice to treat Met-amplified cancers [15]. The gene discussed is MET; the disease is cancer.